Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.96 - $2.94 $34,300 - $51,450
17,500 Added 265.15%
24,100 $65,000
Q2 2024

Aug 14, 2024

SELL
$1.94 - $4.56 $2,716 - $6,383
-1,400 Reduced 17.5%
6,600 $15,000
Q1 2024

May 15, 2024

SELL
$4.33 - $6.06 $5,196 - $7,271
-1,200 Reduced 13.04%
8,000 $37,000
Q4 2023

Feb 14, 2024

SELL
$3.13 - $5.13 $2,817 - $4,617
-900 Reduced 8.91%
9,200 $44,000
Q3 2023

Nov 14, 2023

SELL
$4.24 - $7.44 $15,264 - $26,784
-3,600 Reduced 26.28%
10,100 $46,000
Q2 2023

Aug 14, 2023

SELL
$5.28 - $8.35 $20,592 - $32,565
-3,900 Reduced 22.16%
13,700 $101,000
Q1 2023

May 15, 2023

BUY
$7.6 - $12.68 $60,800 - $101,440
8,000 Added 83.33%
17,600 $143,000
Q4 2022

Feb 14, 2023

BUY
$8.6 - $14.1 $82,560 - $135,360
9,600 New
9,600 $91,000

Others Institutions Holding AKYA

About Akoya Biosciences, Inc.


  • Ticker AKYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 37,892,300
  • Market Cap $94.4M
  • Description
  • Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope...
More about AKYA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.